Gut microbiota and intestinal mucosal barrier

The gut microbiota and intestinal mucosal barrier represent a complex biological interface essential for maintaining systemic homeostasis and immune regulation (Nature Reviews Gastroenterology & Hepatology, 2020). The intestinal mucosal barrier is a multi-layered system comprising a physical mucus layer, a single layer of epithelial cells joined by tight junctions, and an underlying immune layer (Frontiers in Immunology, 2021). The gut microbiota interacts with this barrier by producing metabolites such as short-chain fatty acids (SCFAs) that provide energy to colonocytes and strengthen junctional complexes (Cell Host & Microbe, 2018). Dysregulation of this system, often characterized by increased intestinal permeability (leaky gut) and microbial dysbiosis, is a central factor in the pathogenesis of inflammatory bowel disease (IBD), metabolic syndrome, and certain autoimmune disorders (The Lancet Gastroenterology & Hepatology, 2019). Therapeutic interventions targeting this axis include probiotics, prebiotics, and novel small molecules like Larazotide acetate, which aim to restore barrier integrity and microbial balance (Journal of Clinical Investigation, 2021).

Other names

Gut-intestinal barrier axisIntestinal mucosal interfaceGut microbiome-barrier systemIntestinal epithelial barrier

Therapeutic agents targeting this system work by modulating the composition of the gut microbiota to favor beneficial species, enhancing the expression and assembly of tight junction proteins (e.g., claudins, occludins), stimulating the production of protective mucus layers, and regulating the secretion of antimicrobial peptides and anti-inflammatory cytokines (Nature Reviews Microbiology, 2019; Frontiers in Immunology, 2021).